Featured Spatial & Genomic Sequencing Products
Discover our leading genomic, single-cell, and spatial transcriptomics technologies driving biomedical breakthroughs globally.
Seattle's Leading Role in Spatially Resolved Transcriptomics
Seattle, Washington has firmly established itself as one of the premier global epicenters for biotechnology, molecular diagnostics, and spatial biology innovation. Driven by world-renowned research institutes such as the Allen Institute for Brain Science, the Fred Hutchinson Cancer Center, and the University of Washington (UW) Medicine, the Seattle metropolitan area is at the absolute forefront of the Spatially Resolved Transcriptomics (SRT) revolution. SRT technology bridges the gap between traditional histology and high-throughput sequencing, allowing scientists to map where genes are expressed directly within intact tissue slices.
Traditional bulk RNA sequencing averages cellular expression, losing vital spatial localization data. Single-cell RNA sequencing (scRNA-seq) identifies cell types but requires tissue dissociation, destroying the structural context. Spatially Resolved Transcriptomics retains both single-cell resolution and spatial coordinates, unlocking the cellular microenvironment.
The local industry landscape in Seattle is characterized by a unique synergy between academic research institutions and commercial biotech companies. Local startups and multinational biotech firms in South Lake Union and the surrounding Puget Sound region are actively developing and deploying next-generation spatial platforms. These tools are transforming oncology, neurobiology, and developmental biology research by providing sub-cellular resolution of gene expression in complex tissues.
Key Commercial Players & Tech Advancements in the Pacific Northwest
Seattle is home to pioneering companies like NanoString Technologies (now part of Bruker Spatial Biology), which developed the CosMx™ Spatial Molecular Imager and GeoMx® Digital Spatial Profiler. Additionally, companies like Vizgen and 10x Genomics maintain a strong collaborative footprint here, working alongside local pathologists and researchers. This concentration of spatial biology expertise has accelerated the translation of spatial transcriptomics from bench to clinic, allowing for more precise tumor profiling and personalized therapeutic regimens.
Biomarker Technologies (BMKGene)
Biomarker Technologies (BMKGene), founded in 2009, is a leading genomics service provider with over 16 years of continuous innovation in high-throughput sequencing and bioinformatics. Backed by more than 60 national invention patents and 200+ software copyrights, we deliver comprehensive multi-omics solutions—spanning genomics, metagenomics, epigenetics, single-cell omics, transcriptomics, and our proprietary BMKMANU S3000 spatial transcriptome technology—supported by our advanced BMKCloud bioinformatics platform. We have established long-term collaborations with organizations across 84 regions worldwide, providing reliable genomic solutions on a global scale.
As spatial transcriptomics transitions into sub-cellular and subcellular resolutions, BMKGene's BMKMANU S3000 offers researchers in Seattle and globally an unprecedented window into cellular morphology and transcription. By combining our robust high-throughput sequencing infrastructure with advanced spatial mapping, we empower scientists to visualize gene expression landscapes with absolute spatial fidelity.
Our Leading Multi-level High-throughput Sequencing Platforms
To support advanced spatial transcriptomics and multi-omics studies, BMKGene has built an industry-leading laboratory infrastructure. Our technological capabilities span across various sequencing modalities, ensuring optimal throughput, read lengths, and accuracy for every unique project design.
Advanced Sequencing Systems
PacBio platforms: Sequel II, Sequel, RSII
Nanopore platforms: PromethION P48, GridION X5 MinION
10X Genomics: 10X ChromiumX, 10X Chromium Controller
Illumina platforms: NovaSeq
BGI-sequencing platforms: DNBSEQ-G400, DNBSEQ-T7
Bionano Irys system
Waters XEVO G2-XS QTOF
QTRAP 6500+
Over 20,000 Square Feet Laboratory
Our facility features state-of-the-art biomolecular laboratory instruments. We house standard laboratories dedicated to sample extraction, library construction, clean rooms, and high-throughput sequencing, all operating under strict SOPs to ensure reproducibility and quality control.
Bioinformatic Analysis Platform
Our self-developed BMKCloud platform features extensive computing power to process complex spatial transcriptomics data. Equipped with peak computing capacity over 121,708.8 Gflop per second, 4,260 computing cores, 41,104 memory, and 3 PB total storage.
Localized Application Scenarios of Spatial Biology in Seattle
Spatially resolved transcriptomics is not just a laboratory concept; it is actively driving therapeutic discoveries in Seattle's clinical trials and research labs. Here are the primary local application fields:
Researchers at Fred Hutch utilize spatial profiling to study the boundary layers of solid tumors. By mapping the exact coordinates of infiltrating lymphocytes (T-cells) relative to tumor cells, they can identify mechanisms of immune evasion and predict patient responses to immunotherapy.
The Allen Institute for Brain Science has been instrumental in using spatial transcriptomics to construct the Mouse and Human Brain Atlases. This level of spatial detail helps local scientists understand how Alzheimer's disease progresses by localizing amyloid plaques relative to specific transcriptomic neuronal subtypes.
Beyond human health, Seattle's research network collaborates heavily on plant biology. Spatial transcriptomics allows the analysis of host-pathogen interactions in agricultural crops, mapping gene expression patterns at the site of fungal or viral infection on plant leaves and roots.
Future Industry Trends: The Rise of Spatial Multi-Omics
The next frontier in spatial biology is the integration of multiple omics layers. Rather than sequencing RNA alone, researchers are seeking to map the epigenome, transcriptome, and proteome simultaneously on a single tissue section. This holistic approach, combined with AI-driven deep learning models, will enable researchers to predict cellular behavior and drug responses with unprecedented accuracy. BMKGene is committed to this multi-omics future, integrating spatial transcriptomics with metabolomics and epigenetics to deliver comprehensive biological insights.
Fully Automated Platform for Next-generation sequencing--Brilliant Lab 1000
Biomarker technologies (BMKGENE) and PerkinElmer have jointly built a fully automated experimental production line, called Brilliant Lab 1000 (BL1000), which is applied to the high-throughput NGS library construction service. BMKGENE strives to greatly improve the entire line of sequencing products in terms of product types, production line throughput, delivery quality, and cycle time, to provide customers with better sequencing services.
Industrial Automation in Genomics
By eliminating manual pipetting and human error, the BL1000 platform guarantees high consistency and rapid turnaround times. This is particularly crucial for spatial transcriptomics and large-scale clinical trials where sample preparation consistency is paramount to achieving reliable, reproducible spatial maps.
Enterprise Qualification & Joint Laboratories
Quality and compliance are the cornerstones of BMKGene's global operations. Our laboratories adhere to international standards, backed by continuous validation from leading scientific bodies and instrument manufacturers.
Patents, Certifications & Intellectual Property
Through our relentless focus on R&D, Biomarker Technologies has amassed a significant portfolio of patents and intellectual property. These innovations form the technical foundation of our spatial transcriptomics and NGS pipelines.
